Prospects for Prostate Cancer Chemotherapy: Cytotoxic Evaluation and Mechanistic Insights of Quinolinequinones with ADME/PK Profile

Ayse Tarbin Jannuzzi,Ayse Mine Yilmaz Goler,Abanish Biswas,Subodh Mondal,Vinay N. Basavanakatti,Hatice Yıldırım,Mahmut Yıldız,Nilüfer Bayrak,Venkatesan Jayaprakash,Amaç Fatih TuYuN
DOI: https://doi.org/10.3390/biomedicines12061241
IF: 4.757
2024-06-03
Biomedicines
Abstract:The evaluation of in vitro biological activity of several previously reported quinolinequinones (AQQ1–5) against 60 human cancer cell lines (NCI-60) used by the National Cancer Institute's Developmental Therapeutics Program (DTP) contributed to our earlier research on possible anticancer and/or antibacterial agents. Of interest, NCI-60 screening revealed that two quinolinequinones (AQQ1 and AQQ2) significantly reduced the proliferation of several cancer genotypes. Following the administration of a single dose and five additional doses, all quinolinequinones demonstrated a significant inhibitory effect on the growth of leukemia and other cancer cell lines. Hence, a series of subsequent in vitro biological assessments were performed to further understand the mechanistic impact of the compounds. In MTT assays, it was found that AQQ1 and AQQ2 exhibited higher efficacy against DU-145 cells (IC50 4.18 μM and 4.17 μM, respectively) compared to MDA-MB-231 (IC50 8.27 and 13.33 μM, respectively) and HCT-116 cells (IC50 5.83 and 9.18 μM, respectively). Additionally, AQQ1 demonstrated greater activity in this context. Further investigations revealed that AQQ1 inhibited DU-145 cell growth and migration dose-dependently. Remarkably, arrest of the DU-145 cell cycle at G0/G1 phase and ROS elevation were observed. Pharmacokinetic (PK) studies revealed that AQQ1 has better PK parameters than AQQ2 with %F of 9.83 in rat. Considering the data obtained with human liver microsomal stability studies, AQQ1 should have a better PK profile in human subjects. In silico studies (molecular dynamics) with three kinases (CDK2, CDK4, and MAPK) leading to cell cycle arrest at G0/G1 identified MAPK as a probable target for AQQ1. Taken together, our results showed that AQQ1 could be a potential chemotherapeutic lead molecule for prostate cancer.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
This paper aims to explore the potential of several previously reported quinoline - quinone derivatives (AQQ1 - 5) as chemotherapeutic drugs for prostate cancer. Specifically, through in - vitro bioactivity evaluation and mechanism research, the study investigated the cytotoxic effects of these compounds on 60 human cancer cell lines (used by the Developmental Therapeutics Program of the National Cancer Institute in the United States) and their mechanisms of action, and analyzed their pharmacokinetic (PK) and absorption, distribution, metabolism, excretion (ADME) characteristics. The study found that two of the quinoline - quinone derivatives (AQQ1 and AQQ2) showed significant inhibitory effects on the proliferation of multiple cancer genotypes after single - dose administration and subsequent five - dose administrations, especially on the growth of leukemia and other cancer cell lines. Further research showed that AQQ1 exhibited a dose - dependent effect in inhibiting the growth and migration of DU - 145 cells (a prostate cancer cell line), and could cause the DU - 145 cell cycle to be arrested at the G0/G1 phase and increase the level of reactive oxygen species (ROS). In addition, the pharmacokinetic study of AQQ1 indicated that it had good PK parameters and was expected to also have good PK characteristics in humans. Molecular dynamics simulations suggested that AQQ1 might interact with mitogen - activated protein kinase (MAPK), resulting in cell cycle arrest at the G0/G1 phase. In conclusion, the research results indicate that AQQ1 might be a potential lead molecule for prostate cancer chemotherapy.